Abstract
BackgroundMicroRNAs (miRNAs) are non-coding, single-stranded small RNAs that regulate gene expression negatively, which is involved in fundamental cellular processes. In this study, we investigated the role of miR-490-3P in the development of drug resistance in ovarian cancer cells.MethodsThe human ovarian carcinoma cell line A2780 and A2780/Taxol were exposed to paclitaxel in the presence or absence of microRNA 490-3P transfection, after which cell viability were performed by CCK-8 assay. Reverse transcription polymerase chain reaction (RT-PCR) and western blotting were used to assess the mRNA and protein expression levels of GST-π, MDR1 or P-gp.ResultsOur results showed higher miR-490-3P mRNA expression level in A2780/Taxol cells than in A2780 cells (p < 0.05). Following miR-490-3P transfection, both A2780 and A2780/Taxol cells showed decreased sensitivity to paclitaxel. The mRNA expression levels of MDR1, GST-π (p < 0.05) and protein expression levels of P-gp, GST-π were down-regulated after miR-490-3P transfection in comparison to mock and negative control cancer cells.ConclusionOur results demonstrate for the first time that microRNA 490-3P may be involved in the development of drug resistance in ovarian cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s13048-014-0084-4) contains supplementary material, which is available to authorized users.
Highlights
Ovarian cancer remains the most common cause of death from gynecological malignancies [1,2]
MiR-490-3P down-regulate expression of MDR1/P-gp and glutathione S-transferase (GST)-π Reverse transcription polymerase chain reaction (RT-PCR) results showed that after transfected with mimics of microRNA 490-3P, the mRNA expression levels of MDR1 and GST-π in A2780 and A2780/Taxol cell lines were higher than those observed in negative control cells
Our results showed that the sensitivity of both A2780 and A2780/Taxol cell lines transfected with miR-490-3P mimics to paclitaxel was decreased compared with negative control or mock cells, suggesting that microRNA 490-3P may be involved in the development of drug resistance in ovarian cancer cells
Summary
Ovarian cancer remains the most common cause of death from gynecological malignancies [1,2]. Since numerous patients with ovarian cancer who initially respond to paclitaxel-therapy eventually relapse with a drug-resistant form of the disease, their five-year survival rate was not improved. Zhimin Li et al reported that MiR-27a may up-regualte MDR1/Pglycoprotein expression by targeting HIPK2 in human ovarian cancer cells [19], Li H et al reported that miR-106a may be involved in the development of drug resistance and the regulation of PDCD4 expression [20]. MicroRNAs (miRNAs) are non-coding, single-stranded small RNAs that regulate gene expression negatively, which is involved in fundamental cellular processes. We investigated the role of miR-490-3P in the development of drug resistance in ovarian cancer cells
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
